drugset / Trial / NCT01930812
18F-NaF PET Imaging for Bone Scintigraphy
Phase 3
Completed
286 enrolled
British Columbia Cancer Agency
Canadian Institutes of Health Research (CIHR) · collab
NaSingle-groupOpen-labelDiagnostic
Summary
The purpose of this study is to compare, in patients with prostate or breast cancer, the accuracy of 18F-NaF PET imaging to 99mTc whole body bone scans with single-photon emission computed tomography (SPECT).
Timeline
- Start
- 2014-07
- Primary completion
- 2017-03
- Completion
- 2019-03-31
Outcome
Met primary endpoint
paper 18F-NaF PET-CT was more accurate than 99mTc-MDP SPECT (84·3% [95% CI 79·9-88·7] vs 77·4% [72·3-82·5], difference 6·9% [95% CI 1·3-12·5]; p=0·016). PMID 36343655 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 18F-Sodium Fluoride (NaF) | Diagnostic / imaging agent | 185 mbq | Intravenous |
| Subject | 18F-Sodium Fluoride (NaF) | Diagnostic / imaging agent | 370 mbq | Intravenous |